Table 2.
Therapeutic regimen of studies enrolled.
| Study | RT regimens | Interventions | D-stage resection | |
|---|---|---|---|---|
| NACRT group | NACT group | |||
| Cao MF 2019 (11) | IMRT (40 Gy/20f/4w) |
TC(paclitaxel + carboplatin)+ 40 Gy | TC | D2 |
| Jiang Y 2019 (12) |
IMRT (47–50 Gy/24–25f/5–6w) |
46.8–50.4 Gy concurrently with capecitabine |
Oxaliplatin + capecitabine | – |
| He ZR 2017 (13) |
3D-CRT (45 Gy/25f/5w) |
(5-fluorouracil + folinic acid + oxaliplatin)or capecitabine + 45 Gy |
(5- fluorouracil + folinic acid + oxaliplatin)or capecitabine | – |
| Leong T 2017 (14) | 3D-CRT or IMRT or VMAT (45 Gy/25f/5w) |
(Epirubicin + cisplatin + 5-fluorouracil/capecitabine) + 45 Gy concurrently with 5-fluorouracil/capecitabine |
Epirubicin + cisplatin + 5-fluorouracil/capecitabine | D2 recommended, D1 is the minimum approach |
| Stahl M 2017 (15, 16) | 3D-CRT (30 Gy/15f/3w) |
5-fluorouracil + folinic acid + cisplatin + 30 Gy with cisplatin and etoposide |
5- fluorouracil + folinic acid + cisplatin | D2 |
| Zhang XT 2016 (17) |
IMRT (45 Gy/25f/5w) |
S-1 + docetaxel + 45 Gy | S-1 + docetaxel | D2 |
| Wang X 2016 (18) |
IMRT (45 Gy/22f) |
40.04–45.1 Gy concurrently with S-1 |
SOX (S-1 + oxaliplatin) | – |